Investors
Download Investor Presentation to see how we are shaping the future of Regenerative Medicine
GLOBAL MARKET
One Formula. One Device.
Five Addressable Markets*
Conexeu’s patented extracellular matrix (ECM) platform supports restoration of native tissue, with the opportunity to elevate the standard of care across multiple potential markets*.
Conexeu is a regenerative biotechnology company pioneering a scalable, next generation, natural thermo-sensitive extracellular matrix (ECM) platform
One Technology Multiple Markets
Single-backbone scaffold platform may enable staged expansion across wound care, aesthetics, dental, and biomaterials from one core asset
Validated Technology Platform
(10+ Years R&D) Decade+ preclinical evidence base with published data that may de-risk R&D and accelerate portfolio integration
Defensible IP Moat
(Patented in 40+ Countries) Broad patent protection across 40+ countries creates durable exclusivity and blocks fast-follower replication of the core scaffold
Regulatory Advantage
(510(k) Pathway First) Predicate-based 510(k) strategy likely to compress time-to-market and reduce regulatory spend versus PMA or de novo alternatives
What if?
we could regenerate the tissue lost to aging instead of just filling space?
READY FOR INNOVATION
Market Challenge:
HA Fillers, 90% market share. 22 years
All trademarks are the property of their respective owners. Used solely for identification in connection with publicly available regulatory data. Not an endorsement or affiliation.
Aesthetic injectables have not solved the body contouring need, and can’t fully address the new GLP-1 need for tissue loss.
CXU: A Platform as A Pipeline
Designed to Scale:
One defensible core technology that may generate multiple products by reusing the same IP backbone, manufacturing foundation, and biological logic
Conexeu Mission
A New Paradigm for Injectables: Volume + Regeneration
Designing the ideal injectable with potential for small facial volume indications AND larger body contouring applications
Consumers Are Driving the Market
Consumers Want More Collagen
of research shows* consumers would consider
non-surgical aesthetic treatments
that naturally stimulates collagen production.
Consumers Crave Innovation in Aesthetics
of consumers were triggered to get filler treatments due to new/innovative filler product.*
Aging Well, Not Just Anti-Aging
of customers are focused on looking healthy vs. looking young*. Globally, anti-aging and aesthetic treatments have experienced exponential growth with a focus on Collagen replenishment.
(*See “Future of Aesthetics” Allergan Aesthetics Global Survey 2021)link
PATENTED BIOMIMETIC ECM IP
CXU™ Science Driven | Patent Protected | Pre-Clinical
Designing for real innovation in injectable aesthetics. Developing true tissue regeneration support to rebuild volume and new tissue from the inside out.
GLP-1 Drugs “OZEMPIC” are Driving Global Consumers into Aesthetic Treatments
GLP-1 drugs can trigger aggressive weight loss, stripping facial fat faster than skin can adapt. Bringing new aesthetic challenges, such as sagging skin and facial volume loss —commonly referred to as “Ozempic Face” and “Ozempic Body”.
#OzempicFace describes the hollowed cheeks, loose skin and premature wrinkles that can appear after weight loss.
of consumers who lost weight with GLP-1 medications are now seeking treatments to address loose or sagging skin. This is growing demand for skin tightening and body contouring treatments globally.
Market Reality — Few Players, Massive Void
Conexeu is focusing on the huge demand GLP-1–induced aggressive facial fat-loss has created for new facial filler demand. (“#OzempicFace”).
CXU™ is an investigational biostimulatory collagen gel, being evaluated as a potential option to address GLP-1–related skin laxity by supporting tissue volume restoration.
Vision
Re-define the “regenerative space” with credible biology and better consumer outcomes and become a category builder
Conexeu – The Next Generation.
-
Designed as a Collagen based ECM – CXU™ device candidate is a patented, temperature-gelling scaffold, designed to support native tissue growth rather than simply “fill” space*.
-
Single-Platform, Multi-Market Pipeline – Our one CXU™ formulation is being investigated for multiple billion-dollar applications: injectable facial fillers, large-volume body contouring, tissue reconstruction and repair.
-
Streamlined U.S. Regulatory Plan – Tissue repair targets a 510(k) pathway; aesthetic indications follow under the same formulation, reducing incremental complexity and cost*.
-
Clear Commercial Path – Targeting 5 key markets: wound care first, and the rest to follow.
-
Global IP Estate – Issued patents in the United States, Japan, Europe, and Australia, plus pending claims in Canada, and partnering leverage.
-
Deep Technical Moat – ten years of university-backed R&D and eleven peer-reviewed papers underpin the scaffold’s biocompatibility and bio-stimulatory profile.
-
Multi-Billion-Dollar TAM – If cleared, CXU™ could enter high-growth markets spanning $1.3B+ bio-stimulatory fillers, $10B injectable fillers, $6B advanced wound care, and large body application potential.
-
Seasoned Leadership & Scientific Bench Strength – World-renowned aesthetic surgeon, tissue-engineering PhDs, former CEOs/CMOs of global aesthetics leaders, device veterans with proven FDA-clearance track records.
Conexeu may have the most innovative approach to collagen-based regenerative aesthetics today.
1.
Patented IP
Conexeu’s patented, investigational collagen scaffold targets wound care and aesthetics, offering a non-toxic gel designed to support tissue regeneration—opening multi-billion-dollar, high-margin markets versus conventional fillers or implants.
2.
Multiple High-Value Applications
CXU™ collagen ECM intended to target the multi-billion aesthetic markets, to potentially drive value.
3.
Robust M&A Landscape
The global aesthetic market has seen a surge in mergers and acquisitions, particularly for collagen protected IP. Conexeu’s proven research foundation and patents position the company as an attractive partner or acquisition target within the beauty and regenerative medicine space.
4.
Expert Team & Clinical Backing
Conexeu’s leadership comprises seasoned entrepreneurs, plastic surgeons, and regenerative medicine experts. A decade of R&D, multiple peer-reviewed publications, and ongoing R&D underscore the company’s readiness to disrupt the aesthetics sectors.
“Join Us in Shaping the Future of Regenerative Medicine”
At Conexeu, we’re not just introducing another filler or graft; we’re igniting a paradigm shift in how medicine approaches tissue restoration. From investors seeking high-growth opportunities to clinicians pursuing safer and more effective therapies—everyone benefits from a future driven by true regeneration.
Find Out More
Find Out More
Join our newsletter for regular updates on our progress
"*" indicates required fields
* CXU™ is a device candidate in preclinical development. It has not been submitted to or reviewed by the U.S. Food and Drug Administration. Safety and effectiveness have not been established.
* Terms such as ‘next-generation,’ ‘advanced,’ ‘innovative,’ and ‘bioregenerative’ reflect the Company’s assessment of its technology relative to existing approaches and are not intended as representations of regulatory status, clinical performance, or guaranteed commercial outcomes. CXU™ is an investigational device candidate. Safety and effectiveness have not been established. See Forward-Looking Cautionary Statement.
* Design intent based on preclinical evidence. These findings were generated in controlled laboratory settings and animal models. Animal physiology differs from human physiology, and these findings may not be predictive of clinical performance or safety in humans. Clinical significance has not yet established.
* 1. https://media.market.us/wound-care-devices-market-news 2. https://www.grandviewresearch.com/industry-analysis/aesthetic-injectable-market-report 3. https://www.futuremarketinsights.com/reports/periodontal-market 4. https://www.marketresearch.com/VPA-Research-v4245/Animal-Wound-Care-Size-Share-42060937/ 5. https://www.gminsights.com/industry-analysis/3d-bioprinting-market